TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04945759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isokinetick Exercise, Aussie Current, Russion Current, Plasebo Electirical Stimulasyon
Description: Evaluation and treatment will be done with the Cybex humac device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Isokinetick Exercise, Aussie Current, Russion Current, Plasebo Electirical Stimulasyon
Description: Evaluation and treatment will be done with the Cybex humac device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Isokinetick Exercise, Aussie Current, Russion Current, Plasebo Electirical Stimulasyon
Description: Evaluation and treatment will be done with the Cybex humac device.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Isokinetick Exercise, Aussie Current, Russion Current, Plasebo Electirical Stimulasyon
Description: Evaluation and treatment will be done with the Cybex humac device.
Study: NCT05980728

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT05927844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XH-30002 capsule
Description: receive the study drug until the investigator assessed no longer benefit, toxic intolerance, withdrawal of consent, loss of follow-up, or death, whichever occurred first

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XH-30002 capsule
Description: receive the study drug until the investigator assessed no longer benefit, toxic intolerance, withdrawal of consent, loss of follow-up, or death, whichever occurred first

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatiinb tablet
Description: receive the study drug until the investigator assessed no longer benefit, toxic intolerance, withdrawal of consent, loss of follow-up, or death, whichever occurred first

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatiinb tablet
Description: receive the study drug until the investigator assessed no longer benefit, toxic intolerance, withdrawal of consent, loss of follow-up, or death, whichever occurred first
Study: NCT05930652

Intervention type: DIAGNOSTIC_TEST
Intervention: Psychological tests and psychosocial questionnaires
Description: Assessment of psychological functioning (including well-being, mental health conditions, coping skills), and socio-demographics, academic performance, home, relationships, general health, habits, and attitudes.
Study: NCT04738981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UC-MSC
Description: UC-MSC, iv, 1×10\^6 cells/kg, once a week, for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-CD25 mAb
Description: Anti-CD25 mAb, iv, 20mg，twice in first week and once a week thereafter, for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CD25 mAb
Description: Anti-CD25 mAb, iv, 20mg，twice in first week and once a week thereafter, for 4 weeks.
Study: NCT05971459

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Improvised Active Music Therapy
Description: During the music improvisation process, the accredited music therapist will carefully listen to the participant's initial musical expression, including tempo, rhythmic structure, dynamics, and beat. The accredited music therapist will then join, reflecting or confirming aspects of the participant's musical expression using standard music therapy improvisation techniques such as mirroring, matching, dialoguing, and containing on their electronic instrument. By comparing the participant's and therapist's musical responses over the sessions, it will be possible to identify note frequency, velocity of movement, synchronization, and acquisition of rhythmic complexity.
Study: NCT06360822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ED-LCS
Description: This is a lung cancer educational intervention for patients in the emergency department.
Study: NCT05751746

Intervention type: DRUG
Intervention: Magnesium sulfate
Description: Magnesium sulfate will be administered following a protocol that obstetricians already use in our hospital.
Study: NCT05971459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improvised Active Music Therapy
Description: During the music improvisation process, the accredited music therapist will carefully listen to the participant's initial musical expression, including tempo, rhythmic structure, dynamics, and beat. The accredited music therapist will then join, reflecting or confirming aspects of the participant's musical expression using standard music therapy improvisation techniques such as mirroring, matching, dialoguing, and containing on their electronic instrument. By comparing the participant's and therapist's musical responses over the sessions, it will be possible to identify note frequency, velocity of movement, synchronization, and acquisition of rhythmic complexity.
Study: NCT05937763

Intervention type: OTHER
Intervention: Staffing model
Description: Staffing the hospitals emergency department offload zone with a PCP or RN or current workflow.

Intervention type: OTHER
Intervention: Staffing model
Description: Staffing the hospitals emergency department offload zone with a PCP or RN or current workflow.
Study: NCT05682755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: initial time：platelet count ≥50×10\^9/L after allo-HSCT initial dose: 5 mg oral twice weekly initial adjustment: according to the platelet count tested weekly platelet count ≥50×10\^9/L-increased by 5 mg 20×10\^9/L≤ platelet count \<50×10\^9/L-remains unchanged platelet count \<50×10\^9/L- reduced by 5 mg maximum dose: 20 mg oral twice weekly terminal time: 180 days after allo-HSCT
Study: NCT04811066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Transcranial electrical stimulation device. A weak direct electrical current, up to 2 mA, is passed between two electrodes placed on the scalp. Electrodes are housed in 35 cm2 sponges saturated with 4 ml of saline solution (0.9 % NaCl) per side, per pad.~Stimulation is phased in with a 30-second ramp up of the electrical current to the specified stimulation parameters. Following the specified stimulation period, the current is phased-out with a ramp down of the current. For sham stimulation, the ramp-up and ramp-down periods are retained, but stimulation is switched off during the specified stimulation period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Transcranial electrical stimulation device. A weak direct electrical current, up to 2 mA, is passed between two electrodes placed on the scalp. Electrodes are housed in 35 cm2 sponges saturated with 4 ml of saline solution (0.9 % NaCl) per side, per pad.~Stimulation is phased in with a 30-second ramp up of the electrical current to the specified stimulation parameters. Following the specified stimulation period, the current is phased-out with a ramp down of the current. For sham stimulation, the ramp-up and ramp-down periods are retained, but stimulation is switched off during the specified stimulation period.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial electrical stimulation device. A weak direct electrical current, up to 2 mA, is passed between two electrodes placed on the scalp. Electrodes are housed in 35 cm2 sponges saturated with 4 ml of saline solution (0.9 % NaCl) per side, per pad.~Stimulation is phased in with a 30-second ramp up of the electrical current to the specified stimulation parameters. Following the specified stimulation period, the current is phased-out with a ramp down of the current. For sham stimulation, the ramp-up and ramp-down periods are retained, but stimulation is switched off during the specified stimulation period.
Study: NCT04973644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote monitoring devices+Internet management platform
Description: Remote monitoring devices collects blood glucose, total cholesterol, serum ketones and serum uric acid,then upload data to the platform.
Study: NCT06074276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food: whole almonds
Description: 60 grams or (\~2 oz) will be consumed 5 times per week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Food: non-nut snack
Description: Protein and calorie matched non-nut-based food will be consumed 5 times per week by mouth
Study: NCT05610202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3702 tablets
Description: TQB3702 tablets are selective BTK inhibitors.
Study: NCT04840199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir 240 MG Oral Tablet
Description: 240 mg tablets. Administered orally as two tablets once daily with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir 480 MG Oral Tablet
Description: 480 mg tablet. Administered orally as one tablet once daily with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination ART
Description: ART (antiretroviral therapy) medications will be prescribed by participants' health care providers. ARV medications will not be provided by the study.

Intervention type: DRUG
Group type: OTHER
Intervention: Combination ART
Description: ART (antiretroviral therapy) medications will be prescribed by participants' health care providers. ARV medications will not be provided by the study.
Study: NCT06071949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adezunap
Description: Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
Study: NCT05497973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-health ecosystem of stepped psychosocial care
Description: 1. Screening and monitoring: weekly administration of an emotional state thermometer. If the score is \>5, participants are asked to complete the HADS. If HADS' score \>10, step 2 is assigned. The same procedure is followed for steps 3 \& 4. Participants remain in each step for 2 weeks, and all level changes are preceded by a videoconference with a health professional~2. Online psychoeducation campus: displays co-constructed videos and posts developed by health professionals and patients about LC diagnosis and treatment aspects.~3. Online support community: anonymous survivors with LC diagnoses are included. Professionals and patient mentors supervise and foster debate, peer support, and resolve health Q\&As.~4. Weekly online group psychotherapy led by a clinical psychologist and composed of eight 90-minute sessions. Eligible users are placed on a waiting list, starting when 5-6 users are available.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual psychosocial care
Description: Usual psychosocial care for cancer survivors at ICOHospitalet centre led by a clinical psychologist. Usual psychosocial care consists of 7 individual sessions of 45-60 minutes, with 2-3 weeks of space between sessions, based on Individual Meaning-Centered Psychotherapy (IMCP) for Patients With Advanced Cancer (Breitbart et al., 2012). Moreover, they will be offered the education materials from the 2nd step of the platform, as they are compiled on a website open to all patients and relatives.
Study: NCT05448495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posterior TAP block
Description: Using high-frequency linear ultrasound probe, a total volume of 24 ml (20 ml isobaric bupivacaine 0.5% + 2 ml dexmedetomidine \[0.5 mcg\\kg\] + 2ml dexamethasone \[0.1mg\\kg)\] will be injected at the plane between internal oblique and transversus abdominis near the aponeurosis at the posterior axillary line.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ESPB
Description: Using high-frequency linear ultrasound probe, a total volume of 24 ml (20 ml isobaric bupivacaine 0.5% + 2 ml dexmedetomidine \[0.5 mcg\\kg\] + 2ml dexamethasone \[0.1mg\\kg)\] will be injected at T9 erector spinae plane
Study: NCT04645446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pro-ocular gel
Description: Topical gel in multidose formulation to be applied laterally to the forehead twice a day, morning and night for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pro-ocular gel
Description: Topical gel in multidose formulation to be applied laterally to the forehead twice a day, morning and night for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Topical gel in multidose formulation to be applied laterally to the forehead twice a day, morning and night for 3 months
Study: NCT04232033

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fibroblast growth factor 21 infusion
Description: Infusion of Fibroblast growth factor 21

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion (saline)
Description: Infusion of Saline
Study: NCT06471777

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid removal
Description: Fluid removal during kidney replacement therapy
Study: NCT05418296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A novel digital health device
Description: A videogame-generated virtual world designed for the AD/ADRD care dyad.
Study: NCT06419478

Intervention type: OTHER
Intervention: postoperative symptoms
Description: Observational study, focusing solely on symptom surveys of patients.
Study: NCT06238440

Intervention type: OTHER
Group type: OTHER
Intervention: Splint and taping methods
Description: In the control group (CG), a conventional physiotherapy program will be implemented for 2 weeks. A 10-session treatment will be completed using thermal and electrical agents specified in the program prescribed by the physiotherapist.~Splint group: CG + Splint Rigid taping group: CG+ Rigid taping Kinesiotape: CG+ kinesiotape

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Splint and taping methods
Description: In the control group (CG), a conventional physiotherapy program will be implemented for 2 weeks. A 10-session treatment will be completed using thermal and electrical agents specified in the program prescribed by the physiotherapist.~Splint group: CG + Splint Rigid taping group: CG+ Rigid taping Kinesiotape: CG+ kinesiotape

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Splint and taping methods
Description: In the control group (CG), a conventional physiotherapy program will be implemented for 2 weeks. A 10-session treatment will be completed using thermal and electrical agents specified in the program prescribed by the physiotherapist.~Splint group: CG + Splint Rigid taping group: CG+ Rigid taping Kinesiotape: CG+ kinesiotape

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Splint and taping methods
Description: In the control group (CG), a conventional physiotherapy program will be implemented for 2 weeks. A 10-session treatment will be completed using thermal and electrical agents specified in the program prescribed by the physiotherapist.~Splint group: CG + Splint Rigid taping group: CG+ Rigid taping Kinesiotape: CG+ kinesiotape
Study: NCT05925946

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CURE-DM
Description: 1. This randomized controlled prospective trial will be of 2 years duration where 150 patients with T2DM from urban areas of Delhi will be screened.~2. These subjects will be randomized into two groups by computer-generated randomization list using variable block size.~3. Group A (n, 60, test group)will be received a low-calorie diet along with appropriate exercise counseling; and group B (n, 60, Control group) will be received balanced diet along with exercise advice.
Study: NCT05718856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPO-RAs
Description: After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag, hetrombopag and avatrombopag administration were the same as described in arm description. Complete blood count including platelet count was done once a week. The dose of TPO-RAs was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count \>250×10\^9/L, the TPO-RAs will stop until the platelet count \<100×10\^9/L.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPO-RAs combining anti-CD 20 monoclonal antibody
Description: After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag, hetrombopag and avatrombopag administration were the same as described in arm description.The dose of TPO-RAs was adjusted according to the subject platelet count during the period from week 1 to week 24.~Subjects in TPO-RAs combining anti-CD 20 monoclonal antibody treatment group received single dose infusion of Rituximab 375 mg/m2 within 14 days after enrollment. Subjects weighing less than 30kg will be given Rituximab 100 mg once a week for four times. Ortuzumab at 1000mg/ dose is also recommended for subjects weighing 45kg or greater.~Ps.Participants in the TPO-RAs monotherapy group who have platelet count \< 20×10\^9/L or significant skin and mucosal bleeding at the end of 12 weeks of treatment will be given a single dose of Rituximab 375mg/m2 or Ortuzumab at 1000mg/ dose if weighing 45kg or greater.
Study: NCT06156280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH2929 injection
Description: TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH2929 injection
Description: TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.
Study: NCT04822493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling Aid
Description: Women will watch an educational video regarding expectations for delivery and postpartum care in addition to receiving standard care and counseling.
Study: NCT06156280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH2929 injection
Description: TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.
Study: NCT06399133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm water intake
Description: Nurses assessed the patients' gag and swallow reflexes in the SG. Patients who experienced nausea after reflex assessment were considered to have positive reflexes and were administered warm water. Packaged water was boiled in a kettle and poured into 200 mL disposable cups. After cooling the water to 38-40°C using a thermometer, patients were instructed to drink it within 3 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fiber diet
Description: After initiating oral intake, the patients collaborated with a dietitian to incorporate high-fiber foods containing 30 g of fiber daily into their meal menus.
Study: NCT06156280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH2929 injection
Description: TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH2929 injection
Description: TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH2929 injection
Description: TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH2929 injection
Description: TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH2929 injection
Description: TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH2929 injection
Description: TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Placebo comparator
Study: NCT05580822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase for Injection
Description: intra-arterial TNK infusing after successful thrombectomy for patient with acute basilar artery occlusion via support/access catheter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase for Injection
Description: intra-arterial TNK infusing after successful thrombectomy for patient with acute basilar artery occlusion via support/access catheter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intra-arterial saline infusing after successful thrombectomy for patient with acute basilar artery occlusion via support/access catheter
Study: NCT04960969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time-restricted feeding for 4 weeks
Description: Participants in this group will follow a time-restricted diet for 28 days. Consumption of only non-energy drinks will be allowed for 16 hours. During the 8-hour eating period, there will be no restriction on the content of the diets.
Study: NCT05048173

Intervention type: PROCEDURE
Intervention: Sentinel lymph node mapping and biopsy
Description: Sentinel lymph node mapping with indocyanine green dye followed by biopsy if positive
Study: NCT06399133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal massage
Description: Patients in the SG received abdominal massages twice a day, in the morning from 08:00 to 09:00 and in the evening from 19:00 to 20:00, for 15 min per session, starting one day postoperatively.
Study: NCT05048173

Intervention type: PROCEDURE
Intervention: Lymphadenectomy
Description: Conventional lymphadenectomy
Study: NCT06433973

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Test group 1 - CM+LLLT+VISTA
Description: After obtaining adequate LA exposed root surfaces of treated teeth are to be scaled with curettes to reduce root convexity and undercuts.CM will be placed on the recession defect using minimally invasive technique. LLLT will be applied on the site for 10 sec.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Test group 2 - CM+VISTA
Description: After obtaining adequate LA exposed root surfaces of treated teeth are to be scaled with curettes to reduce root convexity and undercuts. Adequate size of CM will be trimmed and applied over the recession defect using minimally invasive technique and secured with sutures.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control group - SCTG+VISTA
Description: Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage procedure will be done with CTG using minimally invasive access technique.